Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

NCT01151046 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Her2 Negative Breast Cancer Patients

Interventions

DRUG: MM-121
DRUG: Placebo
DRUG: Exemestane

Sponsor

Merrimack Pharmaceuticals